Clinical, molecular and glycophenotype insights in SLC39A8-CDG.
Eleonora BonaventuraRita BaroneLuisa SturialeRosa PasquarielloMaria Grazia AlessandrìAnna Maria PintoAlessandra RenieriCeleste PanteghiniBarbara GaravagliaGiovanni CioniRoberta BattiniPublished in: Orphanet journal of rare diseases (2021)
Clinical, MRI and glycosylation features of patients are consistent with SLC39A8-CDG. We document two novel variants associated with Leigh syndrome-like disease presentation of SLC39A8-CDG. We show, for the first time, a severe neurological phenotype overlapping with that described for SLC39A8-CDG in association with the homozygous A391T missense variant. We observed a spontaneous amelioration of transferrin N-glycome, highlighting the efficacy of MS-based serum glycomics as auxiliary tool for the diagnosis and clinical management of therapy response in patients with SLC39A8-CDG. Further studies are needed to analyse more in depth the influence of SLC39A8 variants, including the common missense variant, on the expression and function of ZIP8 protein, and their impact on clinical, biochemical and neuroradiological features.
Keyphrases
- end stage renal disease
- copy number
- magnetic resonance imaging
- multiple sclerosis
- intellectual disability
- ms ms
- chronic kidney disease
- prognostic factors
- stem cells
- gene expression
- mesenchymal stem cells
- dna methylation
- optical coherence tomography
- protein protein
- brain injury
- small molecule
- long non coding rna
- single molecule
- cell therapy
- case control